http://www.youtube.com/watch?v=Bh67GF4FV_E
As biotech founders attempt to inoculate their teams against the economic and social upheaval of SARS-CoV-2, what is the investment community doing? As the world turns attention toward biotech companies to solve this pandemic, does the synthetic biology industry represent an even richer opportunity? Or will the funding frenzy cool off? SynBioBeta founder John Cumbers talks with four investors at the forefront of synthetic biology:
Wednesday, April 15, 8:10 am Pacifichttp://www.youtube.com/watch?v=xWrHZcq-uiY
The brain is central to our humanity, but when problems arise, we don’t have good tools to work with it. Brain-computer interfaces represent a new class of digital therapeutics, allowing access to the brain in areas like sensory and motor prosthetics, monitoring neuropsychiatric conditions, and smart pharmaceutical delivery. Join SynBioBeta founder John Cumbers for a conversation with Matt Angle, CEO of Paradromics, who will share his company’s technology for helping as many as 10 million patients in the US alone. We’ll be joined by Dr. Loretta Breuning of the Inner Mammal Institute, who will describe the neurochemical basis for happiness, and how each of us can more efficiently interact with our deeper “mammalian” brain to guide our neurochemistry toward more pleasurable states. Also joining us is Adam Marblestone, former CSO of the brain-computer interface company Kernel who is known in the neuroscience field for analyses that attempt to define the physical limits and possibilities of brain-related technologies. We are also joined by Mark Bunger, Lab Agent at Innovation Labs, who will discuss the neurotech entrepreneurial ecosystem and provide context for the interplay of neurotech, synthetic biology, and other deep tech fields.
Wednesday, April 15, 8:55 am Pacific
Lorem ipsum dolor sit amet, consectetur adip elit. Donec posuere dolor massa, pellentesque aliquam nisl facilisis sed.
